Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 24.80 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 09:45PM GMT
Release Date Price: $119.96 (-3.43%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. My name is Gena Wang. I'm SMID Cap biotech analyst at Barclays. Welcome to our second virtual Global Healthcare Conference. First, I wish everyone stay healthy. And I would like to thank all the participants, investors, companies and especially our event team and corporate access team who made this virtual health care conference possible.

And with that, I would like to introduce, our next presenting company is Ultragenyx. With us today, we have Emil Kakkis, Chief Executive Officer. Also, we have Mardi Dier, Chief Financial Officer, with us. I will hand over to you, Emil, for a brief overview of the company.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks, Gena, and happy to be here with you today. Ultragenyx has had a great 2020, even though it was a terrible 2020 overall for the world. But in our 10th year, we managed to now have 4 approvals, 2 of them last year and earned a moat of increasing revenue generation with $271

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot